Latest Breaking News On - Jan swastya abhyan - Page 1 : comparemela.com

Inside Remdesivir puzzle: 6 producers, little supply! Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for manufacturing PB Jayakumar | May 3, 2021 | Updated 19:22 IST Demand for Remdesivir fell to almost nil by January after the first wave of the pandemic in the country Reduction in production due to less demand after the first wave of coronavirus and lack of vigil on the part of the Government to ensure stockpiling led to current Remdesivir crisis, say sources. Gilead Life Sciences, the innovator of the re-purposed drug, had licensed six manufacturers in India to produce the drug. Most of them were dependent on contract manufacturers and their subsidiaries to make the product. Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for manufacturing. Neith

United statesDaarab patelJan swastya abhyanGopakumarg nairZydus cadilaTeva pharmaNational pharmaceutical pricing authorityDepartment of revenue onSupreme courtIndian drug manufacturers associationDr reddy labsGilead sciences united statesSupreme court onGilead life sciencesLife sciencesHetero drugs